Novel and emerging drugs for acute myeloid leukemia Journal Article
| Authors: | Stein, E. M.; Tallman, M. S. |
| Article Title: | Novel and emerging drugs for acute myeloid leukemia |
| Abstract: | Acute myeloid leukemia (AML) is a challenging disease to treat with the majority of patients dying from their illness. While overall survival has been markedly prolonged in acute promyelocytic leukemia (APL), survival in younger adults with other subtypes of AML has only modestly improved over the last twenty years. Physicians who treat AML eagerly await drugs like Imatinib for chronic myeloid leukemia, Cladribine for hairy cell leukemia, and Rituximab for non-Hodgkin Lymphoma which have had an important impact on improving outcome. Recent research efforts have focused on refining traditional chemotherapeutic agents to make them more active in AML, targeting specific genetic mutations in myeloid leukemia cells, and utilizing novel agents such as Lenalidomide that have shown activity in other hematologic malignancies. Here, we focus on reviewing the recent literature on agents that may assume a role in clinical practice for patients with AML over the next five years. © 2012 Bentham Science Publishers. |
| Keywords: | cancer survival; event free survival; treatment outcome; survival rate; unclassified drug; acute granulocytic leukemia; overall survival; leukemia, myeloid, acute; lenalidomide; drug tolerability; fatigue; neutropenia; review; sorafenib; cancer combination chemotherapy; diarrhea; drug efficacy; drug safety; monotherapy; treatment duration; unspecified side effect; antineoplastic agents; clinical trials as topic; disease free survival; cytarabine; drug megadose; neurotoxicity; follow up; antineoplastic agent; clinical practice; animals; low drug dose; multiple cycle treatment; anemia; etoposide; leukopenia; nausea; stomatitis; thrombocytopenia; randomized controlled trials as topic; cytogenetics; continuous infusion; chronic myeloid leukemia; cancer mortality; temsirolimus; febrile neutropenia; gastrointestinal toxicity; survival time; cancer regression; myelodysplastic syndrome; drug mechanism; drug uptake; drug response; mitoxantrone; daunorubicin; vorinostat; 5 aza 2' deoxycytidine; idarubicin; acute lymphocytic leukemia; chromosome deletion; everolimus; cytopenia; clofarabine; azacitidine; gemtuzumab ozogamicin; ecchymosis; phase 2 clinical trial (topic); phase 3 clinical trial (topic); petechia; chromosome 5q; midostaurin; multicenter study (topic); acute myeloid leukemia; liver vein obstruction; cancer prognosis; emerging agents; novel drugs; chemotherapy induced nausea and vomiting; quizartinib; cpx 351; elacytarabine; sapacitabine; vosaroxin |
| Journal Title: | Current Cancer Drug Targets |
| Volume: | 12 |
| Issue: | 5 |
| ISSN: | 1568-0096 |
| Publisher: | Bentham Science Publishers |
| Date Published: | 2012-06-01 |
| Start Page: | 522 |
| End Page: | 530 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 22483153 |
| PMCID: | PMC4030742 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 July 2012" - "CODEN: CCDTB" - "Source: Scopus" |
Citation Impact
Related MSK Work